GSK lifts emerging market bet with full control of Indonesia arm

[riky]

GSK lifts emerging market bet with full control of Indonesia arm

<p><a href="http://news.yahoo.com/gsk-lifts-emerging-market-bet-full-control-indonesia-134849382--sector.html"><img src="http://l1.yimg.com/bt/api/res/1.2/aat_BPTgczYJepgyqpHZJw--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9NzU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2014-03-28T134849Z_1_CBREA2R12DH00_RTROPTP_2_GSK-CHINA.JPG" width="130" height="86" alt="The logo of GlaxoSmithKline is seen on its office building in Shanghai" align="left" title="The logo of GlaxoSmithKline is seen on its office building in Shanghai" border="0" /></a>GlaxoSmithKline is betting more on Indonesia by taking full control of its consumer healthcare unit in the country, underscoring a drive by the drugmaker to build up its presence in fast-growing emerging markets. GSK has paid 465 billion rupiahs ($40 million) to Sarasvati Venture Capital for the 30 percent of the Indonesian consumer healthcare operation it did not previously own, giving it 100 percent of a business that sells non-prescription products like Panadol painkillers and Sensodyne toothpaste. At the same time, GSK has sold its non-core local Insto eye drops brand to Pharma Healthcare and agreed to divest its factory at Bogor, Indonesia, to PT Pharma Healthcare for a combined total of 133 billion rupiahs. &quot;This transaction is a further example of GSK focusing its business in strategically important growth markets such as Indonesia.</p><br clear="all"/>

Source: You are not allowed to view links. Register or Login